The invention encompasses compositions and compounds for inhibiting CoV2 Spike GP and human ACE2 proteins and a 3D pharmacophore model described herein provides the means for rapid, high-throughput virtual screening of potential anti-CoV2 modulators thus facilitating, optimizing and speeding up the search for the discovery of a potent anti-COVID-19 agent and methods of treatment and prevention thereof.

Chronic inflammation is an increasing medical problem area of high socioeconomic significance. The invention relates to a method and a kit for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation, and to a medicament for treating such a patient. To that end, the gene expression of GATA-3 and/or Tbet in a biological isolate of the patient is measured and used for association with a molecular phenotype of the illness.

The present invention provides an oxygenated fatty acyl glycerol for use in treating and/or preventing an inflammatory disease a subject.

The present invention provides an antibody to a fibrosis-related molecule and medical application thereof. The antibody of the present invention is an antibody that binds to CHL1 protein and an antibody that neutralizes the binding of the CHL1 protein to a fibroblast.

Methods for treating inflammatory skin conditions, such as atopic dermatitis and psoriasis, and for promoting skin wound healing and for treating skin wounds, such as thermal and pressure injury, by reducing the activity of Granzyme K.

Subject matter of the present invention is a method for monitoring a therapy in a subject, wherein the subject is under treatment with an anti-Adrenomedullin (ADM) binder selected from the group comprising an antibody, antibody-fragment and/or non-Ig scaffold, comprising determining the level of a fragment of pre-pro-Adrenomedullin selected from the group comprising Midregional Proadrenomedullin (MR-proADM), C-terminal Proadrenomedullin (CT-proADM) and/or Proadrenomedullin N-terminal 20 peptide (PAMP) or fragments thereof in a bodily fluid obtained from said subject; and correlating the level of said fragment of pre-pro-Adrenomedullin with the subject's clinical/medical status of health and/or the risk for an adverse outcome and/or the requirement for adapting therapeutic measures.

The present invention relates to animmunological assay kits for determining the presence or absence, and/or the concentration, of proteasome-complement complex formation in a sample, such as in bodily fluids using a first antibody and a second antibody, wherein the first antibody is immobilized on a carrier and the second antibody is modified with a labeling substance, and the first antibody and the second antibody are selected from an antibody specific for a proteasome protein, such as AF1 or intact proteasome, and an antibody specific for complement factor C3, such as C3, C3c,C3b, iC3b, or an antibody specific for complement factor C4, such as C4, C4b, iC4b or C4c

The disclosed assay can be used for detecting levels of circulating 26S proteasome bound to complement factor 3 or 4 in blood plasma or other body fluids, such as for monitoring levels of inflammation and virus infection in the body of a mammalian, including complement system down regulation in the body of a mammalian as well as for verifying compliance of processed cereals (SPC) and/or functional food with high levels of natural antisecretory protein (NASP).

The disclosure provides methods for selecting patient sub-populations, or subjects, with inflammatory conditions such as inflammatory bowel diseases that are amenable to treatment with anti-Interleukin-23 therapy by measuring the serum levels of Interleukin-22 Binding Protein and/or the serum levels of Interferon-γ. In addition, the methods are useful in identifying sub-populations of patients with inflammatory disorders, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis that are amenable to treatment with an anti-IL-23 therapy and/or an anti-IFN-γ therapy.

The present invention relates to an antibody specifically binding to a tryptophanyl-tRNA synthetase (WRS) protein and, more specifically, to: an antibody, or a fragment of the antibody, specifically binding to a polypeptide of an amino acid sequence represented by SEQ ID NO: 2 in a WRS protein; a polynucleotide encoding the antibody and a vector comprising same; a cell transformed using same; and a use thereof.

The present invention relates generally to the diagnosis, treatment, and monitoring of Chronic Inflammatory Response Syndrome (CIRS), kits for use in the methods, and pharmaceutical compositions for use in the methods of treatment. The invention specifically relates to the diagnosis, treatment and monitoring of CIRS through a comprehensive approach comprising an assessment of a subject for case definition parameters and a proteogenomic analysis. The proteogenomic analysis for the diagnosis, treatment, and monitoring of CIRS is based on identifying proteins and/or genes that are differentially expressed in subjects suffering from CIRS compared to healthy subjects.